Valneva Shares Surge by 6.16%, Approaching a Key Resistance Level Ahead of Earnings
Valneva's stock price marked a significant increase of 6.16% this Tuesday during the session, reaching €4.97, in a Parisian market trending upwards with the CAC 40 gaining 2.16%. This rebound brings the weekly performance of the Nantes-based laboratory to over 7%, and its three-month gain to 31%. The stock is now nearing a critical technical threshold, just days before the announcement of its annual results.
Trading at €4.97, Valneva is now very close to its technical resistance located at €5.08. This level also coincides with the upper Bollinger band (€5.07), reinforcing its significance as a potential friction zone. A clear break through this threshold could pave the way for a new bullish phase, while a rejection would consolidate the hypothesis of a temporary cap. Moreover, the stock is trading well above its 50-day and 200-day moving averages, at €4.28 and €3.78 respectively, indicating a favorable underlying momentum over several months. On a yearly basis, the stock has risen by 48.68%. This movement comes six days before the group's annual 2025 results announcement, scheduled for March 16, which could be a potentially decisive catalyst for the stock's short-term trajectory.
Valneva's Rise in a Generally Favorable Market Session
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Valneva's increase is part of a generally favorable session in European markets. The CAC 40 is up 2.16% during the session, while the German DAX has gained 2.22% and the FTSE 100 has advanced by 1.67%. In Asia, the Nikkei 225 closed up 2.88% and the Hang Seng increased by 2.17%, providing a bullish relay to the Old Continent's exchanges. However, this improvement occurs in a context of increased volatility in global markets. The VIX, a volatility indicator for the S&P 500, was at 29.49 points in its last measurement on March 6, up sharply by 24.17% from the day before, indicating a high level of tension. Valneva's very low beta (0.01) however indicates that historically, the stock has almost no correlation with major indices, which moderates the direct impact of this ambient nervousness on its stock trajectory. The group's general assembly is scheduled for June 1, 2026.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.